Abstract
Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for the treatment of relapsed or refractory CLL or SLL after 2 prior therapies. Here we present the efficacy and safety of duvelisib in patients who had received 2 prior therapies in the phase 3 DUO trial (NCT02004522).
Original language | English |
---|---|
Article number | P-012 |
Pages (from-to) | S9-S10 |
Number of pages | 2 |
Journal | American Journal of Hematology |
Volume | 94 |
Issue number | S2 |
DOIs | |
Publication status | Published - 1 Nov 2019 |
Externally published | Yes |
Keywords
- chronic lymphocytic leukemia
- small lymphocytic lymphoma
- CLL
- SLL
- therapies
- patients
- Duvelisib